Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsBoezio, A.A., Berry, L., Albrecht, B.K., Bauer, D., Bellon, S.F., Bode, C., Chen, A., Choquette, D., Dussault, I., Hirai, S., Kaplan-Lefko, P., Larrow, J.F., Lin, M.H., Lohman, J., Potashman, M.H., Rex, K., Santostefano, M., Shah, K., Shimanovich, R., Springer, S.K., Teffera, Y., Yang, Y., Zhang, Y., Harmange, J.C.
(2009) Bioorg Med Chem Lett 19: 6307-6312
- PubMed: 19819693
- DOI: 10.1016/j.bmcl.2009.09.096
- Primary Citation of Related Structures:
- PubMed Abstract:
Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. H ...
Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase activity and display improved pharmacodynamic profiles. Specifically, the potent time-dependent inhibition of cytochrome P450 associated with the O-linked triazolopyridazines has been eliminated within this novel series of inhibitors. N-linked triazolopyridazine 24 exhibited favorable pharmacokinetics and displayed potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver PD model. Once-daily oral administration of 24 for 22days showed significant tumor growth inhibition in an NIH-3T3/TPR-Met xenograft mouse efficacy model.
Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. email@example.com